Last reviewed · How we verify

Infection of skin AND/OR subcutaneous tissue — Treatment Landscape & Competitive Intelligence

Infection of skin AND/OR subcutaneous tissue (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Infection of skin AND/OR subcutaneous tissue, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Dalvance DALBAVANCIN AbbVie Lipoglycopeptide Antibacterial 2014-01-01
Avelox moxifloxacin Bayer AG Fluoroquinolone antibiotic (fourth-generation) DNA gyrase, DNA gyrase subunit A, DNA topoisomerase 4 subunit A 1999-12-10
ALATROFLOXACIN ALATROFLOXACIN Pfizer alatrofloxacin 1997-01-01
Levaquin levofloxacin Generic (originally Daiichi Sankyo/J&J) Fluoroquinolone Antibacterial [EPC] CAAX prenyl protease 2, Multidrug and toxin extrusion protein 1, Potassium voltage-gated channel subfamily H member 2 1996-12-20
Zosyn TAZOBACTAM Merck Sharp & Dohme B.V. beta Lactamase Inhibitor 1993-01-01
Biaxin clarithromycin Generic (originally Abbott/AbbVie) Macrolide Antimicrobial [EPC] Potassium voltage-gated channel subfamily H member 2 1991-10-31
Cefzil cefprozil Teva Pharmaceuticals USA Cephalosporin Antibacterial [EPC] 1991-01-01
Cipro ciprofloxacin Bayer AG Fluoroquinolone antibiotic DNA topoisomerase II, DNA gyrase subunit A, DNA gyrase subunit A 1987-10-22
Ceftin CEFUROXIME AXETIL GSK Cephalosporin Antibacterial 1987-01-01
Unasyn SULBACTAM Pfizer beta Lactamase Inhibitor Serine beta-lactamase-like protein LACTB, mitochondrial 1986-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. · 19 drugs in Infection of skin AND/OR subcutaneous tissue
  2. Pfizer · 10 drugs in Infection of skin AND/OR subcutaneous tissue
  3. Bristol-Myers Squibb · 7 drugs in Infection of skin AND/OR subcutaneous tissue
  4. GSK · 5 drugs in Infection of skin AND/OR subcutaneous tissue
  5. Merck & Co. · 3 drugs in Infection of skin AND/OR subcutaneous tissue
  6. Merck Sharp & Dohme B.V. · 2 drugs in Infection of skin AND/OR subcutaneous tissue
  7. Bayer AG · 2 drugs in Infection of skin AND/OR subcutaneous tissue
  8. Pai Holdings Pharm · 2 drugs in Infection of skin AND/OR subcutaneous tissue
  9. Astellas Pharma · 1 drug in Infection of skin AND/OR subcutaneous tissue
  10. Bulovka Hospital · 1 drug in Infection of skin AND/OR subcutaneous tissue
  11. Assistance Publique - Hôpitaux de Paris · 1 drug in Infection of skin AND/OR subcutaneous tissue
  12. Advanz · 1 drug in Infection of skin AND/OR subcutaneous tissue

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Infection of skin AND/OR subcutaneous tissue:

Cite this brief

Drug Landscape (2026). Infection of skin AND/OR subcutaneous tissue — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/infection-of-skin-and-or-subcutaneous-tissue. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing